Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of $0.00, $0.07 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $77.4 million versus the consensus estimate of $73.58 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.